|
|
| Benslimane-ahmim, Z.; Heymann, D.; Dizier, B.; Lokajczyk, A.; Brion, R.; Laurendeau, I.; Bieche, I.; Smadja, D. M.; Galy-fauroux, I.; Colliec-jouault, Sylvia; Fischer, Anne-marie; Boisson-vidal, Catherine. |
| Background: Osteoprotegerin (OPG), a soluble receptor of the tumour necrosis factor family, and its ligand, the receptor activator of nuclear factor-kappa B ligand (RANKL), are emerging as important regulators of vascular pathophysiology. Objectives: We evaluated their effects on vasculogenesis induced by endothelial colony-forming cells (ECFC) and on neovessel formation in vivo. Methods: Effects of OPG and RANKL on in vitro angiogenesis were evaluated after ECFC incubation with OPG or RANKL (0-50 ng mL(-1)). Effects on microvessel formation were evaluated with an in vivo murin Matrigel plug assay. Vascularization was evaluated by measuring plug hemoglobin and vascular endothelial growth factor (VEGF)-R2 content 14 days after implantation. Results: We... |
| Tipo: Text |
Palavras-chave: Endothelial colony-forming cells; Osteoprotegerin; Receptor activator of nuclear factor-kappa B ligand; Vasculogenesis. |
| Ano: 2011 |
URL: http://archimer.ifremer.fr/doc/00033/14462/11863.pdf |
| |
